Aclarion provides corporate update highlighting scan volume growth and key upcoming catalysts

Nociscan yoy scan volume increased 132% from q2 2024 to q2 2025 fueled by new physician adoption and insurance company coverage in the uk company has achieved two consecutive quarters of scan volume growth for the first time and expects continued qoq growth for the remainder of the year cost-effectiveness analysis demonstrating nociscan is more effective and less costly than provocative discography published in peer-reviewed journal adding critical evidence in support of payer coverage pivotal clarity trial proceeding on schedule with first patient enrolled to validate nociscan's ability to improve surgical outcomes for chronic low back pain, with internal interim results expected in q2 2026 reaffirms cash runway through q3 2026 to prove out the key catalysts of demonstrating significant scan volume growth and visibility into the success of clarity broomfield, colo., aug. 05, 2025 (globe newswire) -- aclarion, inc., (“aclarion” or the “company”) (nasdaq: acon, aconw), a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (ai) algorithms to help physicians identify the location of chronic low back pain, today announced that scan volume has achieved significant year over year growth of 132% from 2q24 to 2q25 and has demonstrated two consecutive quarters of growth for the first time.
ACON Ratings Summary
ACON Quant Ranking